A new study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate groups and proposed an explanation for how cognitive impairment arises. The findings were just published in Alzheimer's & Dementia®: The Journal of the Alzheimer's Association.
Vascular dementia is the second most common form of dementia following Alzheimer's disease. It has similar symptoms, including problems with memory, decision-making and language, and represents a significant public health problem as the global population continues to age.
The condition is usually caused by cerebral small vessel disease (cSVD), which damages the brain's small blood vessels—but researchers don't yet know the exact mechanism linking cSVD to dementia. One theory involves problems with the glymphatic system, which helps clear waste from the brain.
A team of researchers from the Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), part of the Keck School of Medicine , as well as researchers from the Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) consortium, have found new evidence in support of that theory. With funding from the National Institutes of Health, the group analyzed brain scans and cognitive tests from a total of 3750 people. The researchers then used technique known Diffusion Tensor Image Analysis along the Perivascular Space - or DTI-ALPS - to determine how well the glymphatic system was functioning in each person based on their brain scans. The researchers compared the DTI-ALPS results with the cognitive test results and found that people with lower DTI-ALPS scores also performed lower on cognitive tests. The study confirmed that a low DTI-ALPS score is a biomarker for cSVD and suggests that glymphatic damage may be driving cognitive decline.
"The most significant finding is that we found a clear link between DTI-ALPS and cognitive function in all four cohorts, with ages ranging from middle-age through older adulthood," said Danny J. J. Wang, PhD, the study's senior author and a professor of neurology and radiology and director of imaging technology innovation at the Keck School of Medicine's Stevens INI.
Wang and his team also analyzed the progression of symptoms across study participants, finding a possible pathway to explain how glymphatic problems lead to cognitive impairment. Their results provide a target for clinical researchers seeking to develop treatments for vascular dementia, Wang said, and may also prove useful for treating symptoms of Alzheimer's disease.
Validating the biomarker
The DTI-ALPS biomarker relies on magnetic resonance imaging (MRI) to measure water movement along perivascular spaces, fluid-filled regions around the brain's blood vessels that are a key part of the glymphatic system. If researchers detect changes in DTI-ALPS score, that can indicate damage and suggest that the waste clearance system is not functioning as it should.
In the present study, Wang and his team analyzed MRI scans to collect a measure of DTI-ALPS for each participant. They compared those measurements to each person's level of executive function, a composite score of cognition that includes memory, attention, planning, emotion regulation and other abilities that tend to suffer as dementia progresses.
The researchers found that lower DTI-ALPS scores, which indicated damage to the glymphatic system, were associated with worse executive function. That link was verified independently in four separate participant groups—from the MarkVCID consortium; the University of California, Davis; the University of California, San Francisco; and the Framingham Heart Study—with a total of 3750 participants.
Independently validating the DTI-ALPS biomarker in each of the four cohorts provides strong evidence for the glymphatic system's role in cSVD and vascular dementia, Wang said. The racial and ethnic diversity of the participant groups, as well as the range of ages included (averaging between 56 and 76 years of age across cohorts) also suggests that the findings are robust and can be generalized to a broader patient population.
Treatments for vascular dementia
Once the team linked problems with glymphatic function to declines in executive function, they moved on to the next question — why? To find out more, the researchers conducted a mediation analysis, which studies the process or mechanism connecting two or more variables. In this case, they found that another biomarker—"free water" or excess water in the brain's white matter—helped explain the link between glymphatic problems and cognitive decline.
In this potential pathway, "first waste clearance is impaired, which causes accumulation of free water in the brain's white matter. That leads to tissue damage and eventually to cognitive impairment," said the paper's first author, Xiaodan Liu, MD, PhD, a former postdoctoral researcher at the USC Stevens INI, now an assistant researcher in radiology at the University of California, San Francisco.
More research, including longitudinal work, is needed to confirm whether each step in that pathway is causal. But the team's findings indicate that the DTI-ALPS score biomarker for vascular dementia is robust and ready to be used in clinical trials, Wang said.
Those studies could explore enhancing glymphatic function as a way to treat vascular dementia. Lifestyle changes such as exercising more and improving sleep quality are one way to do that, Wang said, and future studies may also reveal medications that can help. The findings could also provide clues for how to treat Alzheimer's disease, which has been linked to low DTI-ALPS scores in other studies.
About this research
In addition to Wang, the study's other authors are Xiaodan Liu, Xingfeng Shao and Kay Jann from the Laboratory of fMRI Technology, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California; Steven Cen and John M. Ringman from the Department of Neurology, Keck School of Medicine of USC, University of Southern California; Pauline Maillard and Charles S. DeCarli from the University of California, Davis; Giuseppe Barisano from Stanford University; Arvind Caprihan from the Mind Research Network, Albuquerque, New Mexico; Hanzhang Lu from Johns Hopkins University School of Medicine; Konstantinos Arfanakis from the Illinois Institute of Technology and Rush University Medical Center, Chicago, Illinois; Brian T. Gold from the University of Kentucky; Sudha Seshadri, Claudia L. Satizabal and Mohamad Habes from the University of Texas Health Science Center at San Antonio, San Antonio, Texas; Alexa S. Beiser from Boston University; Joel H. Kramer and Lara Stables from the University of California, San Francisco; Herpreet Singh, Kristin Schwab and Steven M. Greenberg from Massachusetts General Hospital, Boston, Massachusetts; and Karl G. Helmer from Harvard Medical School, Massachusetts General Hospital and the Massachusetts Institute of Technology.
This work was supported by the National Institute of Neurological Disorders and Stroke and the National Institute on Aging, part of the National Institutes of Health [U24NS100591, UH3NS100599, UH3NS100605, UH3NS100588, UH3NS100608, UH3NS100606, UH3NS100598 and UH3NS100614]
